Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O5XF
|
|||
| Former ID |
DIB006876
|
|||
| Drug Name |
CeaVac
|
|||
| Synonyms |
Idiotypic vaccine (CEA), Titan; Monoclonal antibody (cancer), Titan
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 2 | [1] | |
| Company |
Titan Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | . | [2] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00003125) Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J Clin Oncol. 1999 Sep;17(9):2889-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.